WO1989003695A1 - Bone cement including a cell growth stimulant - Google Patents
Bone cement including a cell growth stimulant Download PDFInfo
- Publication number
- WO1989003695A1 WO1989003695A1 PCT/DK1988/000170 DK8800170W WO8903695A1 WO 1989003695 A1 WO1989003695 A1 WO 1989003695A1 DK 8800170 W DK8800170 W DK 8800170W WO 8903695 A1 WO8903695 A1 WO 8903695A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bone
- cement
- reaction resin
- growth stimulant
- cell growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
- A61B17/8802—Equipment for handling bone cement or other fluid fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2002/4631—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor the prosthesis being specially adapted for being cemented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
- A61L2300/222—Steroids, e.g. corticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to a bone cement which is useful for healing bone f actures, repairing bone defects and stablisation of prosthetic implants.
- the cement may be mixed with antibiotics, such as Gen- tamicin, in order to avoid infections.
- antibiotics such as Gen- tamicin
- BMP bone or- phogenetic protein
- the present invention is based on the discovery that growth hormone stimulates proliferation of bone cells by increasing the level of IGFl in the "target" cells, and that this effect causes the bone cells to multiply, grow, produce matrix and penetrate into the cement phase.
- a bone cement comprising a combination of physiologi ⁇ cally acceptable reaction resin and a cell growth stimu ⁇ lant, preferably selected from the group consisting of somatotropins, somatomedines, parathyroid hormone (PTH), vitamin D and sex steroids.
- Useful cell growth stimulants may be selected from the following groups:
- Insulin-line growth factor 1 Insulin-line growth factor 1
- the preferred cell growth stimulant to be used in the invention is human growth hormone (hGH). It has been shown that hGH, when it is incorporated in the cement, will increase the rate of healing of a bone fracture considerably and give a joint of increased strength.
- hGH human growth hormone
- reaction resin is used in the present concept to designate any casting resin in fluid, semi-liquid dough-like or ouldable form, capable of being cured or hardened at the temperature of application, usually between 30°C and 45°C, to form a strong, hard or flexible solid.
- a preferred reaction resin is a polymerizing resin, such as a mixture of monomeric methyl methacrylate and pow ⁇ dered polymethyl methacrylate.
- This composition also contains a catalyst and an accelerator.
- examples of other useful resins are unsaturated polyesters or other liquid or mouldable polymerizing unsaturated compounds. Still other examples are ceramics and biodegradable organic galss.
- a polycondensation resin can be used, such as a liquid high viscosity epoxy resin or a mixture of a di- or tri-isocyanate and a di- or trioi, producing a- polyurethane resin.
- a polycondensation resin such as a liquid high viscosity epoxy resin or a mixture of a di- or tri-isocyanate and a di- or trioi, producing a- polyurethane resin.
- Some polyurethane formulations will give a foamed resin, having increased flexibility and a high loading capacity for growth hormone or a similar cell grow ⁇ th stimulant.
- the reaction resin In order to reduce the shrinking of the reaction resin during the curing process it can be mixed with a filler, such as Plaster of Paris or inorganic pigments or fibres. Also other additives, conventionally used in the plas ⁇ tics field, may be added.
- a filler such as Plaster of Paris or inorganic pigments or fibres.
- other additives conventionally used in the plas ⁇ tics field, may be added.
- the reaction resin may be a monomeric cyano acrylate. This material will polymerize very fast at a hydrophiiic surface to a solid having a high bonding strength.
- hGH hGH
- a similar cell growth stimulant Used in total hip replacement surgery, the incorporation of hGH or a similar cell growth stimulant will result in increased bone remodelling and bone formation at the cement surface, leading to increased strength at the bone-cement interface. There is reduced risk of aseptic loosening and improved life time of the prosthesis.
- the cement of the invention can be used in knee, elbow and schoulder replacement surgery or in small joint re- placement, such as fingers, wrists or toes.
- the hGH can be applied to the bone-cement interface using supplying means, such as drainage tubes.
- supplying means such as drainage tubes.
- a bone fracture can be treated in the usual way using a plastic foam.
- a drainage tube could be inserted and after operation a solution of hGH could be introduced to the cement through the drainage tube at a controlled rate.
- the cement loaded with hGH can also be used to fill and repair bone defects and osteotomies.
- the release of hGH from the material can lead to new bone cell formation in these areas.
- This application may require the use of a biodegradable _polymer loaded with hGH-growth factors.
- the release of hGH will cause increased bone cell forma ⁇ tion, the biodegradable polymer will eventually be resorbed and the defect will be filled with new bone.
- hGH-loaded resin such as PMMA
- PMMA can be used to repair bone fractures, give joint increased strength and cause increased bone remodelling in conjunction with devices such a a plate, screw or intermedullary pin.
- a material was made from the following substances:
- the sterile human growth hormone in powder form was added to the powder polymer component of PMMA bone cement and mixed thoroughly.
- the liquid monomer component was then added to the mixture and mixed using a plastics spatula until a "dough-like" consistency was formed.
- the material was then inserted into a pre- viously prepared bone cavity.
- the growth hormone loaded cement was implanted into one femur of adult sandy lop rabbits, with plain cement in the contralateral femur as a control.
- the rabbits were sacrificed and the bone-cement interface examined using transmission electronmicroscop .
- the zirconium dioxide radiopague agent
- the cement appeared clear (Fig. 1).
- some invasion of the cement surface could be seen and new mineral deposited in the cement (Fig. 1).
- a medial parapatellar incision was made and access to the knee patella was dislocated laterally to expose the intercondylar area.
- the femoral medullary cavity was reamed to depth of 2 cm.
- Approximately 0.5 ml of cement was injected into each knee.
- On one side the cement was loaded with growth hor ⁇ mone (see above); plain cement was injected into the • contralaterial femur to act as a control. Further con- trols were used where both femura received plain PMMA cement.
- the patellae were reduced and wounds closed with sutures. Post-operatively rabbits were kept unrestrained in sized cagoes (40 x 40 x 01).
- the rabbits were divided into three groups which were sacrificed using an overdose of Euthatal (100 mg in 5 ml) after 1 month, 2 mohths and 4 months, respectively.
- the femora were removed and processed for histology.
- the sections were prepared to include undecalcified bone and intact bone cement making it possible to examine the bone-cement interface intact. Examination of the histology sections revealed that viable bone was growing in direct contact with the PMMA bone cement. When con ⁇ sidering PMMA as a drug delivery system it is important to establish whether the "target" tissue was in contact with the cement, this was clearly the case.
- the bone-cement interface was found to be composed of between 14-21% mineralised bone, 28-52% osteoid bone and 41-60% cells.
- the knee containing growth hormone loaded PMMA contained a higher percentage of osteoid at the bone-cement interface than in the knee containing plain bone cement. This was statistically significant (P ⁇ 0.01).
- Remodelling of the bone occurs over a period of 4 months after surgery.
- the _in vivo results of the rabbits experiments may be important to the problem of aseptic loosening.
- the pre ⁇ cise mechanism of early loosening is not fully under ⁇ stood, but it has been postulated that the primary cause is the shrinkage of cement in the bone cavity and acco p- anying bone necrosis. Under such circumstances, it would initiate a rapid synthetic response following prosthetic replacement. This was clearly seen in the growth hormone loaded cement series when analysed after one month.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO90901765A NO901765L (en) | 1987-10-23 | 1990-04-20 | BONE CEMENT WITH CELL GROWTH STIMULATING AGENT. |
DK098290A DK98290A (en) | 1987-10-23 | 1990-04-20 | BENCEMENT CONTAINING GROWTH STIMENTS |
FI902042A FI902042A0 (en) | 1987-10-23 | 1990-04-23 | BENCEMENT SOM INNEHAOLLER CELLTILLVAEXTSTIMULANS. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8724897 | 1987-10-23 | ||
GB878724897A GB8724897D0 (en) | 1987-10-23 | 1987-10-23 | Material |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989003695A1 true WO1989003695A1 (en) | 1989-05-05 |
Family
ID=10625798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1988/000170 WO1989003695A1 (en) | 1987-10-23 | 1988-10-24 | Bone cement including a cell growth stimulant |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0386056A1 (en) |
JP (1) | JPH03505406A (en) |
AU (1) | AU629799B2 (en) |
FI (1) | FI902042A0 (en) |
GB (1) | GB8724897D0 (en) |
WO (1) | WO1989003695A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011195A1 (en) * | 1990-02-02 | 1991-08-08 | Novo Nordisk A/S | A method of treating a mammal with a biologically active compound |
WO1991011148A1 (en) * | 1990-02-02 | 1991-08-08 | Troels Torp Andreassen | A method and device for local administration of biologically active substances |
WO1991011196A1 (en) * | 1990-02-02 | 1991-08-08 | Novo Nordisk A/S | A method of treating a mammal with a biologically active compound |
WO1993009819A1 (en) * | 1991-11-18 | 1993-05-27 | Michael Braden | The use of biomaterials for tissue repair |
WO1998019699A1 (en) * | 1996-11-05 | 1998-05-14 | Novo Nordisk A/S | Use of growth hormone or a growth hormone secretagogue for promoting bone formation |
WO2001070256A1 (en) * | 2000-03-24 | 2001-09-27 | Lg Chem Investment, Ltd. | A somatotropin composition with improved syringeability |
US6448315B1 (en) | 1999-02-17 | 2002-09-10 | Bone Support Ab | Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof |
EP1444263A2 (en) * | 2001-11-05 | 2004-08-11 | Eli Lilly And Company | Method for improving stability of a bone-connecting implant |
WO2004071547A1 (en) * | 2003-02-12 | 2004-08-26 | Ethicon Gmbh | Bone filling material comprising anabolic steroid |
EP1767213A2 (en) * | 2001-11-05 | 2007-03-28 | Eli Lilly & Company | Method for improving stability of a bone-connecting implant |
US7417077B2 (en) | 2000-07-17 | 2008-08-26 | Bone Support Ab | Composition for an injectable bone mineral substitute material |
CN101663043A (en) * | 2007-04-27 | 2010-03-03 | 尤尼基因实验室公司 | Promote and keep the method and composition of osteogenesis |
US7935121B2 (en) | 2003-11-11 | 2011-05-03 | Bone Support Ab | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
US7938572B2 (en) | 2004-06-22 | 2011-05-10 | Bone Support Ab | Device for producing a hardenable mass |
US7972630B2 (en) * | 2000-04-11 | 2011-07-05 | Bone Support Ab | Injectable bone mineral substitute material |
US20150150616A1 (en) * | 2009-11-20 | 2015-06-04 | Zimmer Knee Creations, Inc. | Subchondral treatment of joint pain |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
US9730744B2 (en) | 2009-11-20 | 2017-08-15 | Zimmer Knee Creations, Inc. | Method for treating joint pain and associated instruments |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH695985A5 (en) * | 2002-01-21 | 2006-11-15 | Straumann Holding Ag | Surface-modified implants. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526909A (en) * | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
EP0198213A2 (en) * | 1985-03-15 | 1986-10-22 | Yeda Research And Development Company, Ltd. | Method and compositions comprising a vitamin D derivative for the local treatment of bone fractures |
US4620327A (en) * | 1984-07-05 | 1986-11-04 | Caplan Arnold I | Process of adapting soluble bone protein for use in stimulating osteoinduction |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8405155D0 (en) * | 1984-10-16 | 1984-10-16 | Bengt Mjoberg | bone cement |
-
1987
- 1987-10-23 GB GB878724897A patent/GB8724897D0/en active Pending
-
1988
- 1988-10-24 WO PCT/DK1988/000170 patent/WO1989003695A1/en not_active Application Discontinuation
- 1988-10-24 JP JP63508789A patent/JPH03505406A/en active Pending
- 1988-10-24 EP EP19880909521 patent/EP0386056A1/en not_active Withdrawn
- 1988-10-24 AU AU26160/88A patent/AU629799B2/en not_active Ceased
-
1990
- 1990-04-23 FI FI902042A patent/FI902042A0/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526909A (en) * | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
US4620327A (en) * | 1984-07-05 | 1986-11-04 | Caplan Arnold I | Process of adapting soluble bone protein for use in stimulating osteoinduction |
EP0198213A2 (en) * | 1985-03-15 | 1986-10-22 | Yeda Research And Development Company, Ltd. | Method and compositions comprising a vitamin D derivative for the local treatment of bone fractures |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011148A1 (en) * | 1990-02-02 | 1991-08-08 | Troels Torp Andreassen | A method and device for local administration of biologically active substances |
WO1991011196A1 (en) * | 1990-02-02 | 1991-08-08 | Novo Nordisk A/S | A method of treating a mammal with a biologically active compound |
WO1991011195A1 (en) * | 1990-02-02 | 1991-08-08 | Novo Nordisk A/S | A method of treating a mammal with a biologically active compound |
WO1993009819A1 (en) * | 1991-11-18 | 1993-05-27 | Michael Braden | The use of biomaterials for tissue repair |
US5468787A (en) * | 1991-11-18 | 1995-11-21 | Braden; Michael | Biomaterials for tissue repair |
WO1998019699A1 (en) * | 1996-11-05 | 1998-05-14 | Novo Nordisk A/S | Use of growth hormone or a growth hormone secretagogue for promoting bone formation |
US6448315B1 (en) | 1999-02-17 | 2002-09-10 | Bone Support Ab | Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof |
WO2001070256A1 (en) * | 2000-03-24 | 2001-09-27 | Lg Chem Investment, Ltd. | A somatotropin composition with improved syringeability |
US7972630B2 (en) * | 2000-04-11 | 2011-07-05 | Bone Support Ab | Injectable bone mineral substitute material |
US7417077B2 (en) | 2000-07-17 | 2008-08-26 | Bone Support Ab | Composition for an injectable bone mineral substitute material |
EP1444263A2 (en) * | 2001-11-05 | 2004-08-11 | Eli Lilly And Company | Method for improving stability of a bone-connecting implant |
EP1767213A2 (en) * | 2001-11-05 | 2007-03-28 | Eli Lilly & Company | Method for improving stability of a bone-connecting implant |
EP1767213A3 (en) * | 2001-11-05 | 2007-04-25 | Eli Lilly & Company | Method for improving stability of a bone-connecting implant |
EP1444263A4 (en) * | 2001-11-05 | 2005-04-20 | Lilly Co Eli | Method for improving stability of a bone-connecting implant |
WO2004071547A1 (en) * | 2003-02-12 | 2004-08-26 | Ethicon Gmbh | Bone filling material comprising anabolic steroid |
US7935121B2 (en) | 2003-11-11 | 2011-05-03 | Bone Support Ab | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
US7938572B2 (en) | 2004-06-22 | 2011-05-10 | Bone Support Ab | Device for producing a hardenable mass |
US8297831B2 (en) | 2004-06-22 | 2012-10-30 | Bone Support Ab | Device for producing a hardenable mass |
CN101663043A (en) * | 2007-04-27 | 2010-03-03 | 尤尼基因实验室公司 | Promote and keep the method and composition of osteogenesis |
CN101663043B (en) * | 2007-04-27 | 2014-03-12 | 尤尼基因实验室公司 | Methods and compositions for fostering and preserving bone growth |
US20150150616A1 (en) * | 2009-11-20 | 2015-06-04 | Zimmer Knee Creations, Inc. | Subchondral treatment of joint pain |
US9717544B2 (en) * | 2009-11-20 | 2017-08-01 | Zimmer Knee Creations, Inc. | Subchondral treatment of joint pain |
US9730744B2 (en) | 2009-11-20 | 2017-08-15 | Zimmer Knee Creations, Inc. | Method for treating joint pain and associated instruments |
US10271883B2 (en) | 2009-11-20 | 2019-04-30 | Zimmer Knee Creations, Inc. | Method for treating joint pain and associated instruments |
US11006992B2 (en) | 2009-11-20 | 2021-05-18 | Zimmer Knee Creations, Inc. | Method for treating joint pain and associated instruments |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
US10994998B2 (en) | 2013-02-20 | 2021-05-04 | Bone Support Ab | Setting of hardenable bone substitute |
Also Published As
Publication number | Publication date |
---|---|
EP0386056A1 (en) | 1990-09-12 |
GB8724897D0 (en) | 1987-11-25 |
AU2616088A (en) | 1989-05-23 |
FI902042A0 (en) | 1990-04-23 |
AU629799B2 (en) | 1992-10-15 |
JPH03505406A (en) | 1991-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1989003695A1 (en) | Bone cement including a cell growth stimulant | |
US5343877A (en) | Orthopedic implant and method | |
US5147403A (en) | Prosthesis implantation method | |
US4526909A (en) | Polymethylmethacrylate delivery system for bone morphogenetic protein | |
US5824087A (en) | Bone regeneration | |
US6593394B1 (en) | Bioactive and osteoporotic bone cement | |
US5514137A (en) | Fixation of orthopedic devices | |
US6005162A (en) | Methods of repairing bone | |
US20190135696A1 (en) | Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects | |
US5049157A (en) | Reinforced bone cement | |
CN1988923B (en) | Bone substitute compositions and method of use | |
US5004501A (en) | Two phase cement mixture, particularly suitable for othopaedics | |
JP4975934B2 (en) | Injectable bone mineral replacement material | |
US4131597A (en) | Bioactive composite material process of producing and method of using same | |
KR101520114B1 (en) | Fibrin compositions containing strontium compounds | |
AU3433393A (en) | Bone cement having chemically joined reinforcing fillers | |
US20090062423A1 (en) | Orthopaedic cement mixtures with low weight percent polyvinyl alcohol (pva) solution | |
KR20090017636A (en) | Injectable bone void filler | |
JP2002331026A (en) | Orthopaedic filling material and method for using the same | |
WO1991011148A1 (en) | A method and device for local administration of biologically active substances | |
JPS62503148A (en) | bone cement | |
US20130110115A1 (en) | Minimally invasive method and devices for repairing loosened prosthetic implants | |
Deb et al. | Acrylic bone cement: genesis and evolution | |
JP2017520596A (en) | Bone substitute for injection to reinforce implant fixation | |
JP2010526064A (en) | Methods and compositions for nurturing and preserving bone tissue growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI HU JP NO SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988909521 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 902042 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1988909521 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988909521 Country of ref document: EP |